Whitehawk Therapeutics Appoints Margaret Dugan as Chief Medical Officer
Whitehawk Therapeutics appointed Dr. Margaret Dugan as Chief Medical Officer effective December 1, 2025.
Dr. Dugan brings over 30 years of global oncology drug development experience, including leadership roles at Novartis, Dracen Pharmaceuticals, and Schrödinger.
She has overseen more than twelve Phase 1 programs and contributed to regulatory approvals for therapies such as capmatinib and ceritinib.
Dr. Dugan will lead Whitehawk's clinical development efforts, focusing on advancing its antibody-drug conjugate (ADC) portfolio for hard-to-treat cancers.
Her expertise is expected to accelerate clinical studies and the development of innovative cancer therapies.